VYNE Therapeutics Inc (VYNE) — Titan Protect Analysis

VYNE

VYNE Therapeutics Inc

Healthcare · ·

$0.66

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$22M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.41

Based on estimated future earnings — lower means cheaper

Rev Growth

-57.4%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-63.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+205% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About VYNE Therapeutics Inc

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i

https://vynetherapeutics.com

Country: United States Employees: 10 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.008

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0499

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.507

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-47.3%

Historical annualised return based on price data

Max Drawdown

-93.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$1.96

67% below the year high

52W Low

$0.28

133% above the year low

Avg Volume

174,547

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.51

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4,437.2%

Profit from core operations before interest and tax

Free Cash Flow

$-20,111,000

Negative — the business is spending more than it generates

Revenue (TTM)

$454,000

Total revenue over the last 12 months

Net Income

$-21,718,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$2.00

Target Median

$2.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go